IKT · Inhibikase Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | $0 | $260.5K | $123.4K | $698.5K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $29.79M | $17.21M | $13.62M | $12.03M | $893.8K |
| SG&A | $23.56M | $11.38M | $6.73M | $6.22M | $2.62M |
| Total Operating Expenses | $51.97M | $28.59M | $20.35M | $18.25M | $3.52M |
| D&A | $60.5K | $26.3K | $177.4K | $0 | - |
| Operating Income | ($51.97M) | ($28.59M) | ($20.09M) | ($18.13M) | ($2.82M) |
| Interest Expense | - | - | - | - | $29.4K |
| Income Tax | $0 | - | - | - | - |
| Net Income | ($48.26M) | ($27.52M) | ($19.03M) | ($18.05M) | ($2.85M) |
| EPS - Basic | ($0.49) | ($1.16) | ($3.57) | ($4.32) | - |
| EPS - Diluted | ($0.49) | ($1.16) | ($3.57) | ($4.86) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $178.80M | $56.50M | $9.17M | $40.75M | $40.75M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.16M | $943.0K | $646.8K | $1.15M | $1.09M |
| Current Assets | $180.11M | $98.45M | $14.21M | $24.37M | - |
| Total Assets | $181.20M | $98.60M | $14.51M | $24.94M | $42.47M |
| Current Liabilities | $8.30M | $3.73M | $3.44M | $3.70M | $4.05M |
| Long-term Debt | - | - | $381.8K | - | $248.9K |
| Total Liabilities | $8.30M | $3.73M | $3.53M | $3.90M | $4.05M |
| Stockholders' Equity | $172.90M | $94.87M | $10.98M | $21.04M | $38.42M |
| Retained Earnings | ($142.68M) | ($94.42M) | ($66.90M) | ($47.87M) | $29.82M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($27.79M) | ($19.15M) | ($18.09M) | ($17.35M) | ($1.13M) |
| Investing Cash Flow | $2.05M | ($37.00M) | $11.66M | $0 | - |
| Financing Cash Flow | $108.46M | $103.48M | $8.41M | ($204.8K) | $15.06M |
| CapEx | $13.4K | $0 | $14.2K | $243.3K | - |
| Free Cash Flow | ($27.80M) | ($19.15M) | ($18.10M) | ($17.59M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | -7712.0% | -14686.2% | -403.5% |
| EBITDA margin | - | - | -7643.9% | -14686.2% | - |
| Net margin | - | - | -7304.7% | -14625.9% | -407.7% |
| Free cash flow margin | - | - | -6947.9% | -14253.4% | - |
| FCF / Net income | 0.58 | 0.70 | 0.95 | 0.97 | - |
| R&D / Revenue | - | - | 5227.8% | 9749.7% | 128.0% |
| SG&A / Revenue | - | - | 2584.2% | 5036.5% | 375.6% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -26.6% | -27.9% | -131.2% | -72.4% | -6.7% |
| Return on equity | -27.9% | -29.0% | -173.3% | -85.8% | -7.4% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 21.70 | 26.37 | 4.13 | 6.59 | - |
| Quick ratio | 21.70 | 26.37 | 4.13 | 6.59 | - |
| Cash ratio | 21.54 | 15.13 | 2.67 | 11.03 | 10.05 |
| Leverage | |||||
| Debt / Equity | - | - | 0.03 | - | 0.01 |
| Debt / Assets | - | - | 0.03 | - | 0.01 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | -95.9x |
| Equity multiplier | 1.05 | 1.04 | 1.32 | 1.19 | 1.11 |
| Liabilities / Assets | 0.05 | 0.04 | 0.24 | 0.16 | 0.10 |
| Efficiency | |||||
| Asset turnover | - | 0.00 | 0.02 | 0.00 | 0.02 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 1.2x | 0.8x | 0.6x | 3.6x | - |
| P / S | - | - | 26.0x | 612.7x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | -100.0% | 111.0% | -82.3% | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -81.8% | -42.3% | -10.8% | -543.2% | - |
| Net income growth (YoY) | -75.4% | -44.6% | -5.4% | -533.9% | - |
| EPS growth (YoY) | 57.8% | 67.5% | 26.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -45.2% | -5.8% | -2.9% | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 82.3% | 764.2% | -47.8% | -45.2% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Inhibikase Therapeutics against the 5 most active filers in the same SIC group.